GSK plc (GSK,GSK.L), in an update on Zantac (ranitidine) litigation, said Monday that it disagreed with the ruling by the Delaware State Court and will immediately seek an appeal. The decision by the State Court contradicts the Federal Court's Multidistrict Litigation ruling under the same legal standard, which dismissed all cases alleging five cancer types, in December 2022. After analyzing 16 epidemiological studies on human data concerning ranitidine usage, the scientific consensus concludes that there is no consistent or reliable evidence suggesting an increased risk of cancer associated with ranitidine, GSK said.
GSK noted that it will continue to vigorously defend itself against all claims and manage this litigation in the best interests of shareholders. Alongside immediately seeking an appeal to the Delaware Supreme Court, the Company will file motions for dismissal pressing additional defenses, severance of cases, and proof-of-use by claimants; and, at the same time, the company will progress to trials of individual cases.
GSK stated that its capital allocation priorities remain unchanged, and the ruling has no impact on the company's investment plans for growth.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.